Revolutionising Psychiatric Treatment: A Chat with EpiVario's CEO
Episode Overview
EpiVario is developing drugs to treat memory-related psychiatric disorders. The approach targets genetic pathways involved in memory formation. Potential to reduce therapy dropout rates and prevent relapses. Aims to lessen traumatic memory intensity and support psychotherapy. Research is in early stages, backed by significant seed funding.
What we're trying to do is not manipulate existing memories... but inhibit a genetic gene expression process.
In a captivating episode of Mental Health News Radio, host Kristen Sinanta-Walker dives into the complexities of treating psychiatric diseases with Thomas Kim, CEO of EpiVario. EpiVario is pioneering a fresh approach to tackling memory-related psychiatric disorders like PTSD, Alzheimer's, and addiction by targeting genetic pathways involved in memory formation. Thomas shares the company's journey, highlighting the innovative drug development process that aims to lessen the intensity of traumatic memories and enhance the effectiveness of psychotherapy.
The conversation is candid and informative, as Thomas discusses the challenges and hopes associated with developing a new medication in a field often overshadowed by stigma. He passionately explains how their research could potentially reduce dropout rates in therapy and prevent relapses by addressing the root causes of these disorders.
With humour and empathy, Kristen navigates the interview, drawing parallels between the proposed drug and existing therapies like EMDR, while ensuring clarity on the drug's role as an adjunct to psychotherapy. This episode is a must-listen for anyone interested in mental health advancements and those curious about the future of psychiatric treatment. It offers a unique perspective on how science is striving to improve lives by tackling complex mental health issues at their core.
Don't miss out on this enlightening conversation that might just change your view on mental health treatment.